Page 128 - 2021_09-Haematologica-web

E. Derenzini et al.
lymphoma. Hematol Oncol. 2019; 37(S2):36-
37.
18. Davies A, Cummin TE, Barrans S, et al.
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL- B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649-662.
19.Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxoru- bicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-3467.
20. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxoru- bicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-3459.
21. taiger AM, Ziepert M, Horn H, et al. Clinical impact of the Cell-of-Origin Classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35(22):2515-2526.
22. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues, Revised 4th edition. 2017. IARC Press, Lyon.
23. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.
24. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B- cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.
25. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct path- ogenic mechanisms and outcomes. Nat Med. 2018;24(8):679-690.
26. Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like dif- fuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190-201.
27. Sha C, Barrans S, Cucco F, et al. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37(3):202-212.
28. Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018; 131(21):2307-2319.
29. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12-23.
30. Paul J, Soujon M, Wengner AM, et al. Simultaneous inhibition of PI3Kδ and PI3Kα induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-κB and AKT. Cancer Cell. 2017;31(1):64-78.
31. Pfeifer M, Grau M, Lenze D, et al. PTEN loss defines a PI3K/AKT pathway-dependent ger- minal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(30):12420-12425.
Stat Assoc.1958;53(282):457-481.
38.Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer
Inst. 1993;85(9):704-710.
39. R Core Team. R: a language and environ-
ment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2014. URL http://www.R-project.org/.
40. Oeckinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harbor Perspectives in Biology. 2009;1(4):a000034.
41. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007; 109(7):2700-2707.
42. Packham G. The role of NF-kappaB in lym- phoid malignancies. Br J Haematol. 2008;143(1):3-15.
43. McConkey DJ, Zhu K. Mechanisms of pro- teasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11(4-5):164-
32. Compagno M, Lim WK, Grunn A, et al.
Mutations of multiple genes cause deregula- 179.
tion of NF-kappaB in diffuse large B-cell lym-
phoma. Nature. 2009;459(7247):717-721.
33. Pan YR, Chen CC, Chan YT, et al. STAT3- coordinated migration facilitates the dissem- ination of diffuse large B-cell lymphomas.
Nat Commun. 2018;9(1):3696. 34.Cortelazzo S, Tarella C, Gianni AM, et al.
44. Mujtaba T, Dou QP. Advances in the under- standing of mechanisms and therapeutic use of bortezomib. Discov Med. 2011;12(67): 471-480.
45. Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lym- phoma. Leuk Lymphoma. 2014; 55(2):415-
Randomized trial comparing R-CHOP versus
high-dose sequential chemotherapy in high-
risk patients with diffuse large B-cell lym-
phomas. J Clin Oncol. 2016; 34(33):4015- 424. 4022.
35. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high- risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, ran- domised, controlled, phase 3 study. Lancet Oncol. 2017;18(8):1076-1088.
46. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6): 904-917.
47. Derenzini E, Mondello P, Erazo T, et al. BET inhibition-induced GSK3β feedback enhances lymphoma vulnerability to PI3K inhibitors. Cell Rep. 2018;24(8):2155-2166.
48.Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromod- omain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014;111(31):11365-11370.
36. 37.
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359(22):2313-2323.
Kaplan EL, Meier P. Nonparametric estima- tions from incomplete observations. J Am
2416
haematologica | 2021; 106(9)